Duke Radiation Oncology is proud to represent our Department during ASTRO 2020. Please see below for presentations and posters from our faculty and staff.
Oral presentations
October 24
1:15 – 2:25 p.m.
Manisha Palta, MD • PRO 04 - Gastrointestinal Cancer: Case Based Discussion
October 25
9:00 – 10:00 a.m.
Wentao Wang, MS (MPGP) • Fluence Map Prediction for Fast Pancreas Stereotactic Body Radiation Therapy (SBRT) Planning via Deep Learning
9:00 – 10:00 a.m.
Chenyang Liu, MS (Duke Kunshan) • An Encoder-Decoder Based Deep Learning AI agent for Spatial Dose Distribution Prediction: A Study of Complex Head-and-Neck IMRT Application
9:45 a.m.
Bridget Koontz, MD • ASTRO Scientific Review 2020 (Speaker)
11:15 a.m.
Bridget Koontz, MD • PRO 08: (SA-CME) Prostate Cancer: Case Based Discussion (Speaker)
2:15 p.m.
Sua Yoo, PhD • Clinical Experience of the Machine Learning-Based Automated Treatment Planning Tool for Breast Radiotherapy
October 26
11:30 a.m – 12:30 p.m.
Manisha Palta, MD • Quick Pitch – Hypofractionation in GI Cancers
12:30 – 12:40 p.m.
Fang-Fang Yin, PhD • Applications and Quality Assurance Consideration for Lung Clinical Trials Using Radiomics
12:30 – 1:00 p.m.
Bridget Koontz, MD • Organizer, Women in GU Virtual Get Together at Virtual ASTRO
12:30 – 1:45 p.m.
Rachel Blitzblau, MD, PhD • The Impact of Neoadjuvant Therapeutics on the Surgical, Medical Oncological and Irradiation Approaches to Breast Cancer Treatment
2:13 p.m.
Junzo Chino, MD • Cervical Cancer Guideline
4:30 – 5:30 p.m.
Grace Kim, MD, PhD • Outcomes in Patients with 4-10 Brain Metastases Treated with Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study
October 27
12:45 – 1:45 p.m.
Brad Ackerson, MD • Treatment of Mycosis Fungoides using a Recumbent Total Skin Electron Beam Technique: A Comparison of Dosimetric and Clinical Outcomes
12:45 p.m.
Jeremy Price, MD, PhD • Effective pain control with very low dose palliative radiotherapy for multiple myeloma patients with painful osseous lesions
2:00 p.m.
Jeremy Price, MD, PhD • Radiation Therapy and Immune Checkpoint Inhibition in Metastatic Non-Small Cell Lung Cancer: Determining Toxicity and Efficacy of Combination Treatment
October 28
12:00 – 1:15 p.m.
Jiahan Zhang, PhD • Quantifying the progression of clinical knowledge with a knowledge-based tradeoff model
1:00 p.m.
Junzo Chino, MD • Challenging Cases in Uterine Cancer
Posters (discussion, presentations and eposters)
October 25, 2:15 – 3:15 p.m.
Cui, Yang, Yin, Yoo, Kim, Duan: Evaluation of Two Automated Treatment Planning Techniques for Multiple Brain Metastases Using A Single Isocenter
Qiuwen Wu and Xiaomin Liang. A Novel AP/PA Total Body Irradiation Technique Using Abutting IMRT Fields at Extended SSD
Jiahan Zhang, Chunhao Wang, Yang Sheng, Jiang Zhang, Manisha Palta, Brian Czito, Christopher Willett, Yaorong Ge, Fang-Fang Yin, Q. Jackie Wu: Simulating planners’ interactions with the treatment planning system: a reinforcement learning study for pancreas SBRT planning
October 25, 4:45 – 5:45 p.m.
David Carpenter, MD, MHS • Long-Term Experience in an Equal Access Health Care System Using Moderately Hypofractionated Radiotherapy for High Risk Prostate Cancer in a Predominately African American Population with Unfavorable Disease
Jeremy Price, MD, PhD • Deciphering the role of MerTK in sarcomagenesis and response to radiation and immune checkpoint therapy
October 26, 4:40 – 5:30 p.m.
Divya Natesan, MD • Ipsilateral versus Bilateral Neck Radiation Therapy for Tonsillar Squamous Cell Carcinoma.
October 27, 2:00 – 3:00 p.m.
Andrew Fairchild, MD • Primary Mediastinal (Thymic) Large B-cell Lymphoma: The Working Diagnosis vs WHO Classification Criteria
October 27, 4:30 – 5:30 p.m.
John Kirkpatrick, MD, PhD • Preserving Neurocognition without Compromising Tumor Control during Whole-Brain Radiotherapy Therapy in Patients with Numerous Brain Metastases via a Novel Superoxide Dismutase Mimetic: Initial Safety Lead-In and Design of a Clinical Trial; Kirkpatrick, Floyd, et al.
October 28, 2:00 – 3:00 p.m.
Divya Natesan, MD • Does Efficacy and Toxicity Differ According to Prostate Volume in Men Treated with Moderately Hypofractionated Radiation Therapy?
Neville Eclov, PhD • Challenges of the clinical machine learning implementation for the prospective System for High Intensity EvaLuation During Radiation Therapy (SHIELD-RT) study
